Last reviewed · How we verify
A Prospective Study of Anti-PD-1 Alone or Combined Wih Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.Furthermore,to characterize response to therapy we intent to evaluate the role of cell-free DNA (cfDNA) and immune repertoire based on the next generation sequencing.
Details
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2016-09 |
| Completion | 2023-06 |
Conditions
- Neoplasms
Interventions
- Anti-PD-1 plus DC-CIK
- Anti-PD-1 alone
Primary outcomes
- Overall survival of the participants(OS) — 24 months
From starting date of anti-PD-1 antibody treatment until date of death from any cause
Countries
China